Bionano Genomics' Next-Gen Platform Set to Boost Throughput by 13x: Future of Cytogenetic Analysis Underway
Portfolio Pulse from Vandana Singh
EF Hutton has initiated coverage of Bionano Genomics (NASDAQ:BNGO) with a Buy rating and a price target of $1.75. BNGO's optical genome mapping (OGM) platform is set to disrupt cytogenetic analysis, targeting a global market of 10,000 labs. The company is releasing a next-generation, high-throughput OGM platform, expected to increase throughput by 13x.
May 25, 2023 | 6:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton initiates coverage of Bionano Genomics with a Buy rating and a $1.75 price target. BNGO's next-gen OGM platform is expected to increase throughput by 13x, targeting a global market of 10,000 labs.
The Buy rating and price target of $1.75 by EF Hutton indicate a positive outlook for Bionano Genomics. The next-generation OGM platform's expected 13x increase in throughput and targeting of a global market of 10,000 labs suggest strong growth potential for the company, which could positively impact its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100